Table 1.
Characteristics of subjects by Fiebig and 4th generation enzyme immunoassay staging system at the time of acute HIV infection diagnosis and week 24 after initiating antiretroviral therapy
| |
Fiebig stages |
4thG stages |
|||||
|---|---|---|---|---|---|---|---|
| |
Stage I |
Stage II |
Stage III |
Stage IV |
Stage 1 |
Stage 2 |
Stage 3 |
| NAT+/p24-/3rd G-(n=25) | NAT+/P24+/3rd G-(n=7) | NAT+/p24±/3rd G+/WB-(n=29) | NAT+/p24±/3rd G+/WB IND (n=2) | NAT+/4th G-/3rd G-(n=20) | NAT+/4th G+/3rd G-(n=12) | NAT+/4th G+/3rd G+/WB- or IND (n=31) | |
|
At time of acute HIV infection diagnosis (n=63) | |||||||
| Median (IQR) days from history of HIV exposure |
14 (9–18) |
15 (11–17) |
18* (13–22) |
26 (NA) |
12 (9–15) |
17* (15–21) |
18* (13–22) |
| Range (Min-Max) |
(4–40) |
(9–18) |
(9–33) |
(20–32) |
(4–40) |
(10–34) |
(9–33) |
| Median (IQR) HIV RNA, log10copies/mL |
5.1 (4.1-5.4) |
5.8 * (5.1-6.5) |
5.9 ** (5.6-6.9) |
5.6 (NA) |
4.8 (3.7-5.4) |
5.8** (5.4-6.2) |
5.8** (5.6-6.9) |
| Range (Min-Max) |
(2.8-6.1) |
(5.1-7.6) |
(4.7-7.7) |
(5.5-5.8) |
(2.8-5.7) |
(5.1-7.6) |
(4.7-7.7) |
| Median(IQR) p24 pg/mL |
3.9 (0–20.1) |
190** (124–794) |
262** (46.1-937.2) |
106 (NA) |
0.3 (0–27.4) |
54.3* (14.7-203.5) |
227.3** (42.6-937.2) |
| Range (Min-Max) |
(0–65) |
(74.3-862) |
(15.7-6973.9) |
(16.9-195) |
(0–133.9) |
(3.7-862) |
(15.7-6973.9) |
| Median(IQR) CD4 cells/mm3 |
413 (311–565) |
289 (218–426) |
381 (298–428) |
371 (NA) |
451 (316–592) |
316 (265–420) |
381 (295–463) |
| Range (Min-Max) |
(214–1127) |
(179–569) |
(132–621) |
(279–463) |
(218–1127) |
(179–698) |
(132–621) |
|
At week 24 after antiretroviral therapy (n=61, excluded 2 subjects who did not start treatment)* | |||||||
| Median (IQR) days from diagnosis to ART initiation |
2 (2–3) |
2 (1–2) |
2 (1–3) |
2 (NA) |
2 (2–4) |
2 (1–2) |
2 (1–3) |
| Range (Min-Max) |
(0–5) |
(0–2) |
(0–5) |
(1–3) |
(1–5) |
(0–4) |
(0–5) |
| Median (IQR) HIV RNA |
1.7 |
1.7 |
1.7 |
1.7 |
1.7 |
1.7 |
1.7 |
| log10copies/mL |
(1.7-1.7) |
(1.7-1.7) |
(1.7-1.7) |
(NA) |
(1.7-1.7) |
(1.7-1.7) |
(1.7-1.7) |
| Range (Min-Max) |
(1.7-1.7) |
(1.7-2.0) |
(1.7-2.2) |
(1.7-1.7) |
(1.7-1.7) |
(1.7-2.0) |
(1.7-2.2) |
| Median change (IQR) HIV RNA log10copies/mL |
-3.4 (-3.7 to -2.4) |
-3.8* (-4.7 to -37) |
-4.2 ** (-5.2 to -3.9) |
-3.9 (-4.1 to -3.8) |
-3.0 (-3.7 to -1.9) |
-4.0* (-4.4 to -3.7) |
-4.1** (-5.2 to -3.8) |
| Range (Min-Max) |
(-4.4 to -1.1) |
(-4.8 to -3.4) |
(-6.0 to -3.0) |
(-4.1 to -3.8) |
(-4.0 to -1.1) |
(-4.8 to -3.4) |
(-6.0 to -3.0) |
| Median (IQR) CD4 cells/mm3 |
600 (540–904) |
766 (523–772) |
579 (486–730) |
821 (NA) |
597 (483–794) |
904* (556–1056) |
579 (470–765) |
| Range (Min-Max) |
(312–1084) |
(354–1145) |
(301–1229) |
(462–1180) |
(312–979) |
(503–1145) |
(301–1229) |
| Median change (IQR) CD4 cells/mm3 |
256 (50–358) |
344 (203–477) |
227 (180–320) |
450 (NA) |
136 (-25 to 280) |
477** (291–719) |
227* (180–347) |
| Range (Min-Max) |
(-237-766) |
(136–719) |
(-135-804) |
(183–717) |
(-237-383) |
(203–766) |
(-135-804) |
| Nonreactive 2nd generation EIA, N |
10 |
0 |
4 |
1 |
9 |
1 |
5 |
| Nonreactive/IND WB, N | 11 | 0 | 4 | 1 | 11 | 0 | 5 |
P value compared to stage 1 within each staging system: *p < 0.05, **p < 0.001 All patients had non-reactive 2nd generation enzyme immunoassay, negative/indeterminate Western Blot and positive nucleic acid testing.
Abbreviations used: NAT nucleic acid testing; 3rdG 3rd generation enzyme immunoassay; 4thG 4th generation enzyme immunoassay; EIA enzyme immunoassay; WB Western blot; IND indeterminate; IQR inter-quartile range; NA not applicable.
*Two patients did not start ART; they were both in Fiebig II stage while one was in 4thG stage1 and the other in 4thG stage2.